Page 105 - Read Online
P. 105

Tessari et al. J Cancer Metastasis Treat 2020;6:18  I  http://dx.doi.org/10.20517/2394-4722.2020.32                           Page 9 of 11

               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2020.


               REFERENCES
               1.   Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7-34.
               2.   Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J
                   Clin 2019;69:363-85.
               3.   Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and
                   mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
               4.   Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, et al. NCCN guidelines insights: non-small cell lung cancer, Version
                   4.2016. J Natl Compr Canc Netw 2016;14:255-64.
               5.   Masters GA, Temin S, Azzoli CG, Giaccone G, Baker S Jr, et al. Systemic therapy for stage IV non-small-cell lung cancer: american
                   society of clinical oncology clinical practice guideline update. J Clin Oncol 2015;33:3488-515.
               6.   Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature 2018;553:446-54.
               7.   Jonna S, Subramaniam DS. Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update. Discov Med
                   2019;27:167-70.
               8.   Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung
                   Cancer Res 2015;4:36-54.
               9.   Giri A, Walia SS, Gajra A. Clinical trials investigating immune checkpoint inhibitors in non-small-cell lung cancer. Rev Recent Clin
                   Trials 2016;11:297-305.
               10.  Meng X, Liu Y, Zhang J, Teng F, Xing L, et al. PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and
                   challenges. Cancer Lett 2017;405:29-37.
               11.  Ramamurthy C, Godwin JL, Borghaei H. Immune checkpoint inhibitor therapy: what line of therapy and how to choose? Curr Treat
                   Options Oncol 2017;18:33.
               12.  Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med
                   2018;50:165.
               13.  Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N
                   Engl J Med 2017;376:2415-26.
               14.  Santana-Davila R, Chow LQ. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer. Future Oncol
                   2018;14:191-4.
               15.  Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, et al. Nivolumab monotherapy for first-line treatment of advanced non-small-
                   cell lung cancer. J Clin Oncol 2016;34:2980-7.
               16.  Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-
                   cell lung cancer. N Engl J Med 2016;375:1823-33.
               17.  Remon J, Besse B, Soria JC. Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small
                   cell lung cancer? BMC Med 2017;15:55.
               18.  Breimer LH, Nousios P, Olsson L, Brunnstrom H. Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell
                   lung cancer: promise, controversies and ambiguities in the novel treatment paradigm. Scand J Clin Lab Invest 2020; doi:
                   10.1080/00365513.2020.1742369:1-10.
               19.  Hendriks LE, Rouleau E, Besse B. Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with
                   immunotherapy. Transl Lung Cancer Res 2018;7:647-60.
               20.  Zarogoulidis P, Papadopoulos V, Maragouli E, Papatsibas G, Sardeli C, et al. Nivolumab as first-line treatment in non-small cell lung
                   cancer patients-key factors: tumor mutation burden and PD-L1 >/=50. Transl Lung Cancer Res 2018;7:S28-30.
               21.  Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer.
                   N Engl J Med 2018;379:2040-51.
               22.  Gridelli C, Casaluce F. The combination strategies will be ready the right first-line choice for squamous lung cancer patients? Transl Lung
                   Cancer Res 2018;7:S349-51.
               23.  Passiglia F, Bironzo P, Scagliotti GV. First-line immune-chemotherapy combination: the right strategy to fight squamous non-small cell
                   lung cancer? Transl Lung Cancer Res 2019;8:546-9.
               24.  Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung
                   cancer. N Engl J Med 2018;378:2078-92.
               25.  Garon EB. Cancer immunotherapy trials not immune from imprecise selection of patients. N Engl J Med 2017;376:2483-5.
               26.  Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res
                   2015;3:436-43.
               27.  Salemi LM, Loureiro SO, Schild-Poulter C. Characterization of RanBPM molecular determinants that control its subcellular localization.
                   PLoS One 2015;10:e0117655.
   100   101   102   103   104   105   106   107   108   109   110